Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Mark A. Goldsmith Sells 11,738 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Mark A. Goldsmith sold 11,738 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $458,251.52. Following the completion of the transaction, the insider now owns 441,564 shares in the company, valued at $17,238,658.56. The trade was a 2.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Revolution Medicines Trading Up 1.5 %

RVMD stock opened at $38.75 on Thursday. Revolution Medicines, Inc. has a 1-year low of $29.55 and a 1-year high of $62.40. The business’s 50 day moving average is $40.74 and its 200-day moving average is $45.78. The firm has a market cap of $7.20 billion, a P/E ratio of -10.79 and a beta of 1.46.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.11). Sell-side analysts forecast that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Institutional Trading of Revolution Medicines

Hedge funds have recently modified their holdings of the company. California State Teachers Retirement System raised its stake in shares of Revolution Medicines by 1.0% in the fourth quarter. California State Teachers Retirement System now owns 113,036 shares of the company’s stock worth $4,944,000 after acquiring an additional 1,104 shares during the last quarter. Jefferies Financial Group Inc. acquired a new stake in shares of Revolution Medicines during the 4th quarter worth approximately $994,000. Polar Asset Management Partners Inc. raised its stake in shares of Revolution Medicines by 46.0% during the fourth quarter. Polar Asset Management Partners Inc. now owns 34,600 shares of the company’s stock worth $1,513,000 after buying an additional 10,900 shares during the last quarter. Mackenzie Financial Corp lifted its stake in shares of Revolution Medicines by 17.1% in the 4th quarter. Mackenzie Financial Corp now owns 6,055 shares of the company’s stock valued at $265,000 after purchasing an additional 885 shares during the period. Finally, GF Fund Management CO. LTD. bought a new position in shares of Revolution Medicines in the 4th quarter worth $154,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on RVMD shares. JPMorgan Chase & Co. lifted their price objective on Revolution Medicines from $63.00 to $71.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 3rd. HC Wainwright upped their price target on Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, March 3rd. Wedbush restated an “outperform” rating and issued a $67.00 price objective on shares of Revolution Medicines in a research note on Thursday, February 27th. Guggenheim upped their target price on shares of Revolution Medicines from $82.00 to $87.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Finally, Stifel Nicolaus dropped their price objective on shares of Revolution Medicines from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. Twelve analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Revolution Medicines currently has a consensus rating of “Buy” and a consensus price target of $66.31.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.